



TOPLINE & METHODOLOGY

Ipsos Psychedelic Science Poll

Conducted by Ipsos using KnowledgePanel®
A survey of the American general population (ages 18+)
Interview dates: May 16-18, 2025
Number of interviews: 1,024

Margin of error: +/- 3.3 percentage points at the 95% confidence level for all respondents

NOTE: All results show percentages among all respondents, unless otherwise labeled. Reduced bases are unweighted values.

NOTE: * = less than 0.5%, - = no respondents, N/A = not applicable

Annotated Questionnaire:

1. Medical research on the use of psychedelic compounds such as MDMA, Psilocybin (mushrooms), and LSD to treat a variety of medical and mental health conditions such as PTSD, Depression, Anxiety, and palliative care, has been growing in recent years. Clinical outcomes are promising, but there are many factors that could impact future availability of these treatments (patient awareness, legal regulations, patient trust, social stigma).

Prior to this survey, how familiar were you with medical research using psychedelic compounds, such as MDMA, Psilocybin, or LSD, to treat mental health disorders?

	Total
Very familiar	5%
Somewhat familiar	23%
Not very familiar	27%
Not at all familiar	44%

2. How do you feel about the use of psychedelics in the following situations?

- a. For medical use, only when prescribed by a health care practitioner and combined with mental health therapy

	Total
Strongly approve	19%
Somewhat approve	33%
Neither approve nor disapprove	29%
Somewhat disapprove	6%
Strongly disapprove	10%



TOPLINE & METHODOLOGY

- b. For medical use, only when prescribed by a health care provider with no requirement for therapy

	Total
Strongly approve	10%
Somewhat approve	25%
Neither approve nor disapprove	32%
Somewhat disapprove	16%
Strongly disapprove	15%

- c. For wellness, such as retreats or as a way to optimize one's health and wellbeing

	Total
Strongly approve	9%
Somewhat approve	20%
Neither approve nor disapprove	36%
Somewhat disapprove	14%
Strongly disapprove	18%

- d. For religious or spiritual use by official churches or other religious or spiritual groups

	Total
Strongly approve	7%
Somewhat approve	11%
Neither approve nor disapprove	37%
Somewhat disapprove	16%
Strongly disapprove	27%

- e. For cultural use by groups who have traditionally used psychedelics

	Total
Strongly approve	11%
Somewhat approve	13%
Neither approve nor disapprove	40%
Somewhat disapprove	13%
Strongly disapprove	21%

- f. For all adults over a certain age, like tobacco

	Total
Strongly approve	8%
Somewhat approve	14%
Neither approve nor disapprove	33%
Somewhat disapprove	16%
Strongly disapprove	27%

TOPLINE & METHODOLOGY

3. How much would you trust each of the following people or organizations for information about psychedelics?

a. Law enforcement

	Total
Do not trust	40%
Somewhat trust	36%
Mostly trust	16%
Fully trust	4%

b. Policy makers or politicians

	Total
Do not trust	70%
Somewhat trust	23%
Mostly trust	4%
Fully trust	1%

c. My primary care provider

	Total
Do not trust	11%
Somewhat trust	35%
Mostly trust	32%
Fully trust	19%

d. My therapist, psychiatrist, or mental healthcare provider

	Total
Do not trust	14%
Somewhat trust	38%
Mostly trust	28%
Fully trust	15%

e. My health insurance company

	Total
Do not trust	43%
Somewhat trust	38%
Mostly trust	12%
Fully trust	3%

TOPLINE & METHODOLOGY

f. Pharmaceutical companies

	Total
Do not trust	47%
Somewhat trust	39%
Mostly trust	8%
Fully trust	2%

g. Government health agencies, such as the Veterans Health Administration, National Institutes of Health (NIH), or the Food and Drug Administration (FDA)

	Total
Do not trust	27%
Somewhat trust	43%
Mostly trust	23%
Fully trust	4%

h. My friends or family

	Total
Do not trust	21%
Somewhat trust	41%
Mostly trust	25%
Fully trust	10%

i. Social media

	Total
Do not trust	72%
Somewhat trust	21%
Mostly trust	3%
Fully trust	1%

j. News sources, such as newspapers, radio, and TV

	Total
Do not trust	44%
Somewhat trust	42%
Mostly trust	10%
Fully trust	1%

k. Peer exchanges online, such as Reddit

	Total
Do not trust	61%
Somewhat trust	29%
Mostly trust	5%
Fully trust	1%

TOPLINE & METHODOLOGY

4. How have perceptions about psychedelics changed in your community in the last two years?

	Total
Trust has increased around psychedelics	13%
Trust has stayed the same around psychedelics	66%
Trust has decreased around psychedelics	14%
Not sure	5%

5. In your opinion, which of the following groups or individuals should receive access to psychedelics **for medical or mental health treatment**? *Please select all that apply.*

	Total
Myself	23%
My loved ones or friends	24%
Society	54%
No one should have access to psychedelics for medical or mental health treatment	34%

a. Myself

	Total
Yes	23%
No	71%
Skipped	6%

b. My loved ones or friends

	Total
Yes	24%
No	70%
Skipped	6%

c. Society

	Total
Yes	54%
No	41%
Skipped	6%

d. No one should have access to psychedelics for medical or mental health treatment

	Total
Yes	34%
No	61%
Skipped	6%

TOPLINE & METHODOLOGY

6. In your opinion, which of the following groups or individuals should receive access to psychedelics **for any purpose**? *Please select all that apply.*

	Total
Myself	16%
My loved ones or friends	14%
Society	34%
No one should have access to psychedelics for any purpose	54%

- a. Myself

	Total
Yes	16%
No	78%
Skipped	6%

- b. My loved ones or friends

	Total
Yes	14%
No	79%
Skipped	6%

- c. Society

	Total
Yes	34%
No	60%
Skipped	6%

- d. No one should have access to psychedelics for any purpose

	Total
Yes	54%
No	39%
Skipped	6%

7. If psychedelics were approved by the FDA and available for prescribed clinical use, and your healthcare provider recommended it for you, would you be open to trying psychedelics as a treatment for a mental health or medical condition?

	Total
Yes	30%
No	31%
Not sure	38%

TOPLINE & METHODOLOGY

8. If psychedelics were approved by the FDA and available for prescribed clinical use, and your healthcare provider recommended it for you, would you have any of the following concerns about using psychedelics in **medical and mental health treatment**? *Please select all that apply.*

	Total
Having a potentially negative experience	58%
Experiencing a negative outcome	53%
Difficulty trusting in your provider	14%
Perceptions or judgements of your friends, family, or community	14%
Potential side effects (known and unknown)	64%
Having the time to dedicate to treatment	12%
Cost of the treatment	41%
Concerns about the place where you would receive treatment	21%
Effectiveness of treatment	43%
Another concern	3%
No concerns	13%

- a. Having a potentially negative experience

	Total
Yes	58%
No	39%
Skipped	3%

- b. Experiencing a negative outcome

	Total
Yes	53%
No	44%
Skipped	3%

- c. Difficulty trusting in your provider

	Total
Yes	14%
No	83%
Skipped	3%

- d. Perceptions or judgements of your friends, family, or community

	Total
Yes	14%
No	82%
Skipped	3%

TOPLINE & METHODOLOGY

e. Potential side effects (known and unknown)

	Total
Yes	64%
No	33%
Skipped	3%

f. Having the time to dedicate to treatment

	Total
Yes	12%
No	85%
Skipped	3%

g. Cost of the treatment

	Total
Yes	41%
No	56%
Skipped	3%

h. Concerns about the place where you would receive treatment

	Total
Yes	21%
No	75%
Skipped	3%

i. Effectiveness of treatment

	Total
Yes	43%
No	54%
Skipped	3%

j. Another concern

	Total
Yes	3%
No	94%
Skipped	3%

k. No concerns

	Total
Yes	13%
No	84%
Skipped	3%

TOPLINE & METHODOLOGY

9. In your opinion, are the typical and current mental health treatments (oral medications and talk therapies), sufficient for treating mental health conditions such as depression, anxiety and PTSD?

	Total
Yes, current treatments are sufficient	17%
No, current treatments are not sufficient	37%
Don't know	45%



TOPLINE & METHODOLOGY

About the Study

This Ipsos poll was conducted from May 16-18, 2025, using the probability-based KnowledgePanel®. This poll is based on a nationally representative probability sample of 1,024 adults age 18 or older.

The survey was conducted using KnowledgePanel, the largest and most well-established online probability-based panel that is representative of the adult U.S. population. Our recruitment process employs a scientifically developed addressed-based sampling methodology using the latest Delivery Sequence File of the USPS – a database with full coverage of all delivery points in the U.S. Households invited to join the panel are randomly selected from all available households in the U.S. Persons in the sampled households are invited to join and participate in the panel. Those selected who do not already have internet access are provided a tablet and internet connection at no cost to the panel member. Those who join the panel and who are selected to participate in a survey are sent a unique password-protected log-in used to complete surveys online. As a result of our recruitment and sampling methodologies, samples from KnowledgePanel cover all households regardless of their phone or internet status and findings can be reported with a margin of sampling error and projected to the general population.

The data for the total sample were weighted to adjust for gender by age, race/ethnicity, education, Census region, metropolitan status, and household income. The demographic benchmarks came from the 2024 March Supplement of the Current Population Survey (CPS).

- Gender (Male, Female) by Age (18–29, 30–44, 45-59 and 60+)
- Race/Hispanic Ethnicity (White Non-Hispanic, Black Non-Hispanic, Other, Non-Hispanic, Hispanic, 2+ Races, Non-Hispanic)
- Education (Less than High School, High School, Some College, Bachelor's degree, Master's degree or higher)
- Census Region (Northeast, Midwest, South, West)
- Metropolitan status (Metro, non-Metro)
- Household Income (Under \$25,000, \$25,000-\$49,999, \$50,000-\$74,999, \$75,000-\$99,999, \$100,000-\$149,999, \$150,000+)

The margin of sampling error is plus or minus 3.3 percentage points at the 95% confidence level, for results based on the entire sample of adults. The margin of sampling error takes into account the design effect, which was 1.14.

The margin of sampling error is higher and varies for results based on sub-samples. In our reporting of the findings, percentage points are rounded off to the nearest whole number. As a result, percentages in a given table column may total slightly higher or lower than 100%. In questions that permit multiple responses, columns may total substantially more than 100%, depending on the number of different responses offered by each respondent.





TOPLINE & METHODOLOGY

About Ipsos

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing over 18,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers or employees. Our 75 solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

Our tagline "Game Changers" sums up our ambition to help our 5,000 customers move confidently through a rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD).

ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP www.ipsos.com

